Drug Maker Prices Secondary Offering (GALE)
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Galena develops cancer drugs and plans to use the net proceeds from this offering for:
working capital and other general corporate purposes, including the Phase 3 NeuVax(TM) (E75) PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment) clinical trial, Phase 1/2 clinical trials of Foliate Binding Protein-E39 (FBP) and a planned Phase 2 trial of NeuVax in combination with Herceptin(R) (trastuzumab; Genentech/Roche).
Shares are down -14% at $1.61 in a 52-week range of $0.36-$3.54.
Contact [email protected] for any questions or corrections.




